SAMe may alleviate chronic colitis

SAMe may alleviate chronic colitis

Have you heard of “chronic colitis”? This intestinal disorder causes recurring abdominal pain and diarrhea, not only impacting quality of life but also potentially increasing the risk of colon cancer over time. While current treatments can alleviate symptoms, they often fail to cure the condition and may carry side effects. However, a new study points to a potential breakthrough: S-adenosyl-L-methionine (SAMe) may act as a protective shield for damaged intestines through its anti-inflammatory and antioxidant properties.

00a3451806da4b0b88d799e63e7c2b3a_ppomub2ftlf

A study published in the journal Cureus utilized Swiss albino mice as experimental subjects to simulate human chronic colitis. Researchers first induced the disease in mice through a specific method: administering water containing 2% dextran sulfate sodium (DSS) for 7 days, followed by switching to regular water for 7 days. This cycle was repeated three times (totaling 42 days), successfully establishing a chronic colitis model. Subsequently, 32 mice were divided into four groups: a normal control group, a disease control group, a positive control group (treated with the clinically used drug sulfasalazine), and a SAMe experimental group.

 

Throughout the experiment, researchers closely monitored the disease activity index (DAI), which comprehensively reflects disease severity based on factors like body weight change and fecal consistency. At the conclusion of the study, they also measured the colon weight-to-length ratio, intestinal tissue lesion severity, and levels of two key biomarkers: the pro-inflammatory factor TNF-α and the antioxidant glutathione (GSH).

 

The results were surprisingly positive! Compared to the disease control group, mice administered SAMe exhibited significantly reduced DAI scores, indicating marked alleviation of symptoms such as diarrhea and weight loss. The ratio of colon weight to length approached normal levels, suggesting substantial relief from intestinal edema and inflammation. Additionally, intestinal tissue showed fewer ulcers and reduced inflammatory cell infiltration, reflecting significant improvement in lesion severity. Regarding biomarkers, SAMe simultaneously reduced pro-inflammatory TNF-α levels while elevating antioxidant GSH levels, thereby mitigating intestinal damage through dual mechanisms. Crucially, these protective effects of SAMe were comparable to those of sulfasalazine, a commonly used clinical medication.

 

SAMe is not a novel substance; it has long been used as a dietary supplement to support the treatment of depression, osteoarthritis, and liver disease. This study provides the first evidence confirming its protective effects against chronic colitis with a high safety profile. However, these findings are currently limited to animal studies, and further clinical research is needed to validate its efficacy in human patients. Regardless, this research opens new avenues for treating chronic colitis and offers renewed hope for improving gut health through natural substances.